AbbVie (NYSE: ABBV) announced longer-term follow-up results from Phase 3 studies of IMBRUVICA (ibrutinib) in chronic lymphocytic leukemia and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American SJune 6, 2016 9:02 AM Cowen Cuts Abbvie (ABBV) to Market Perform; Analyst Calls Rova-T Data at ASCO 'Underwhelming'June 6, 2016 7:36 AM S&P 500 ends at seven-month high after Yellen commentsJune 6, 2016 7:33 AM AbbVie (ABBV) Issues Positive Update on Rova-T as r/r SCLC TreatmentJune 6, 2016 6:26 AM AbbVie (ABBV) Announces Positive ABT-414 Phase 1 Data in Aggressive Brain Cancer June 6, 2016 6:13 AM AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual MeetinJune 5, 2016 9:00 AM Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell LJune 5, 2016 7:30 AM